TAD After Chemotherapy in Locally Advanced Breast Cancer

NCT05763641 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 162

Last updated 2025-09-10

No results posted yet for this study

Summary

This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).

Conditions

Interventions

PROCEDURE

Target Axillary Dissection

TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection

Sponsors & Collaborators

  • Hospital Universitari de Bellvitge

    lead OTHER

Principal Investigators

  • amparo Garcia-Tejedor, MDPhD · Instituto de Investigación Biomédica de Bellvitge (IDIBELL)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2026-06-01
Completion
2026-06-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05763641 on ClinicalTrials.gov